This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Handlungsempfehlungen zur individuellen Risikoermittlung von Komorbidität bei erwachsenen Patienten mit Psoriasis
Die Dermatologie Open Access 22 February 2023
-
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases
BMC Medical Genomics Open Access 08 January 2009
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Murray CJ, Lopez AD . Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436–1442.
Szmitko PE et al. New markers of inflammation and endothelial cell activation: Part I. Circulation 2003; 108: 1917–1923.
Szmitko PE et al. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 2003; 108: 2041–2048.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
Ridker PM . High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813–1818.
Du Clos TW . Function of C-reactive protein. Ann Med 2000; 32: 274–278.
Danesh J et al. Low grade inflammation and coronary heart. BMJ 2000; 321: 199–204.
Dernellis J, Panaretou M . Relationship between C-reactive protein concentrations during glucocorticid treatment and recurrent atrial fibrillation. Eur Heart J 2004; 25: 1100–1107.
Willerson JT, Ridker PM . Inflammation as a cardiovascular risk factor. Circulation 2004; 109(21 Suppl 1): II2–II10.
Liuzzo G et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. disease: prospective study and updated meta-analyses. N Engl J Med 1994; 331: 417–424.
Ridker PM et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230–235.
Di Napoli M, Papa F . Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 2003; 34: 2922–2929.
Torzewski J et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18: 1386–1392.
Van Popele NM et al. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke 2001; 32: 454–460.
Herrington DM et al. Relationship between arterial stiffness and subclinical aortic atherosclerosis. Circulation 2004; 110: 432–437.
Oliver JJ, Webb DJ . Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol 2003; 23: 554–566.
Duprez DA et al. Relationship between C-reactive protein and arterial stiffness in asymptomatic population. J Hum Hypertens [E-pub ahead of print, 19 May 2005; doi:10.1038/sj.jhh.1001860].
Yasmin MCM et al. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004; 24: 969–974.
Mattace-Raso FU et al. C-reactive protein and arterial stiffness in older adults: the Rotterdam Study. Atherosclerosis 2004; 176: 111–116.
Hommels MJ . C-reactive protein, atherosclerosis, and kidney function in hypertensive patients. J Hum Hypertens [E-pub ahead of print, 21 April 2005; doi:10.1038/sj.jhh.1001878].
Bautista LE . Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003; 17(4): 223–230.
Schram MT et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J Hum Hypertens [E-pub ahead of print, 13 January 2005; doi:10.1038/sj.jhh.1001812].
King DE et al. Elevation of C-reactive protein in people with prehypertension. J Clin Hypertens 2004; 6: 562–568.
Bautista LE, Vera LM, Arenas IA, Gamarra G . Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005; 19: 149–154.
Bautista LE et al. C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19: 857–861.
Bautista LE, Atwood JE, O'Malley PG, Taylor AJ . Association between C-reactive protein and hypertension in healthy middle-aged men and women. Coronary Artery Dis 2004; 15: 331–336.
Sung KC et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16: 429–433.
Li X et al. Gender-specific association between pulse pressure and C-reactive protein in a Chinese population. J Hum Hypertens 2005 Jan 27 [Epub ahead of print].
He FJ, MacGregor GA . Cost of poor pressure control in the UK: 62000 unnecessary deaths per year. J Hum Hypertens 2003; 17: 455–457.
Willaims B et al. British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society 2004-BHS IV. J Hum Hypertens 2004; 18(3): 139–185.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Boos, C., Lip, G. Elevated high-sensitive C-reactive protein, large arterial stiffness and atherosclerosis: a relationship between inflammation and hypertension?. J Hum Hypertens 19, 511–513 (2005). https://doi.org/10.1038/sj.jhh.1001858
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001858
This article is cited by
-
Handlungsempfehlungen zur individuellen Risikoermittlung von Komorbidität bei erwachsenen Patienten mit Psoriasis
Die Dermatologie (2023)
-
Inflammation does not influence arterial stiffness and pulse-wave velocity in patients with coronary artery disease
Journal of Human Hypertension (2013)
-
Hypertensive emergencies are associated with elevated markers of inflammation, coagulation, platelet activation and fibrinolysis
Journal of Human Hypertension (2013)
-
Inflammatory biomarkers CRP, MCP-1, serum amyloid alpha and interleukin-18 in patients with HTN and dyslipidemia: impact of diabetes mellitus on metabolic syndrome and the effect of statin therapy
Hypertension Research (2013)
-
Serum C-reactive protein level and prehypertension in two Asian populations
Journal of Human Hypertension (2013)